Navigation Links
First Patient Dosed with KX2-391 in Phase 1 Clinical Trial
Date:11/27/2007

BUFFALO, N.Y., Nov. 27 /PRNewswire/ -- Kinex Pharmaceuticals LLC, announced today that their drug KX2-391 (KX01) has begun Phase 1 human testing. The study is entitled "A combined rising single-dose (RSD) and rising multiple-dose (RMD) Phase 1 study to evaluate safety, tolerability and pharmacokinetics of KX2-391 in patients with advanced malignancies that are refractory to conventional therapies". The drug belongs to an emerging new family of targeted cancer treatments called protein kinase inhibitors.

Dosing has begun at Roswell Park Cancer Institute in Buffalo, N.Y., and will commence in the next several days at M.D. Anderson Cancer Center in Houston, Texas. The trial is expected to enroll 50 patients with advanced solid tumors and lymphoma and will evaluate safety, tolerability and pharmacokinetics. Exploratory biomarker studies will also be involved.

"What's remarkable about this compound is that, in preclinical testing, it has worked against every cancer and in every animal model," said David Hangauer, a University at Buffalo chemistry professor whose work was integral to the drug's creation. Hangauer is a co-founder of Kinex and serves as the Company's Senior Vice President of Research and Development. KX2-391 targets an important cell signaler called Src kinase, a protein linked to the rapid growth and spread of cancer cells. A potential advantage of Kinex's kinase inhibitor is that it disrupts Src at a site different from where other currently studied compounds are targeted, reducing the chance that patients will develop resistance to the new drug, Hangauer said.

"As we go further in the drug's development, and do broader testing, we get better and better data," said Allen Barnett, Chief Executive Officer of Kinex Pharmaceuticals. "We are extremely enthusiastic about the potential for KX2-391 because it represents a unique approach for the treatment of cancer. It is a first-in-class drug that has the potential to provide patients with a safe and effective treatment for a broad range of tumor types," said Barnett.

Contact: Lyn Dyster

Kinex Pharmaceuticals,

(716) 881-8984


'/>"/>
SOURCE Kinex Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... Lilly and Company (NYSE: LLY ) today announced that ... regimen patent would not presently be infringed by Actavis marketing ... Italy and Spain ... solution.  --> --> ... that Lilly,s patent would be indirectly infringed by Actavis marketing ...
(Date:2/12/2016)... februari 2016 AAIPharma Services Corp./Cambridge ... van productie en ontwikkeling op maat voor ... een uitbreiding aan van steriele vul- en ... Charleston, SC . Substantiële ... recente investeringen. http://photos.prnewswire.com/prnh/20150806/256637LOGO ...
(Date:2/12/2016)... 12, 2016 --> ... Chronic Inflammation Global Clinical Trials Review, H2, 2015 ... global clinical trials landscape along with top level ... Country (G7 & E7), Trial Status, Trial Phase, ... top companies involved and enlists all trials (Trial ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Vail knee specialist Robert LaPrade, MD, ... in 2016 . The list consists of physicians establishing, leading and partnering with ambulatory ... , An Ambulatory Surgery Center, also known as an ASC, is a modern ...
(Date:2/12/2016)... ... February 12, 2016 , ... For Coast Dental dentist Everet Lake, DDS, ... dental assistant Terrell Moore shortly before 7 a.m. to volunteer at Friday’s Dentistry from ... their time and skills to help hundreds of uninsured and underinsured people receive much-needed ...
(Date:2/12/2016)... ... 2016 , ... Homeowners now have a next generation tool ... leading brand of building products, has improved upon its industry-best array of home ... of the ColorView® Exterior Style and Color Selector. Created expressly for the iPad®, ...
(Date:2/12/2016)... (PRWEB) , ... February 12, 2016 , ... ... creating explosive growth in the field of long term care. With that, says ... for well-trained healthcare professionals in administrative roles in long term care environments. His ...
(Date:2/12/2016)... ... , ... Dignity Health named Dr. Scott Bingham the Facility Medical Director of ... is licensed under Dignity Health Arizona General Hospital , which opened last year ... ensure our new freestanding emergency room delivers the highest quality care to Mesa and ...
Breaking Medicine News(10 mins):